Accuray Incorporated (PRNewsFoto / Accuray Incorporated) (PRNewsFoto / Accuray Incorporated)

Accuray announces the submission of Tomo® C registration to the National Medical Products Administration of China

SUNNYVALE, California.And the November 1, 2022 /PRNewswire/- Accuray Inc. (NASDAQ: ARAY) in the present day introduced that the registration file for the CNNC-Accuray joint venture Tomo® The Kind B market C radiotherapy system has been submitted to the China Nationwide Medical Merchandise Administration (NMPA). This achievement is in keeping with the schedule that Accuray despatched in the course of the firm’s fourth-quarter fiscal yr 2022 earnings name. Tomo C availability is topic to assessment and approval by the NMPA. new in China It’s particularly designed to develop entry to precision radiotherapy for extra most cancers sufferers in Chinais the primary joint product.

The variety of new most cancers circumstances recognized in China It’s anticipated to extend by roughly 50 % from 2020 to 20401With a rise within the incidence of not solely lung most cancers, but additionally colorectal, breast and prostate most cancers2. Radiation remedy is among the major therapy choices for lung, breast and prostate most cancers, reinforcing the necessity for progressive new approaches to successfully handle the illness whereas minimizing the dangers of uncomfortable side effects and their affect on high quality of life.

“The introduction of the Tomo C file is a vital step for the CNNC-Accuray three way partnership and represents an vital catalyst for progress for Accuray. I’m assured that the system will considerably improve the three way partnership’s product portfolio and considerably competitiveness and the fast-growing Kind B section sooner or later. The crew’s focus is on Making certain we now have the appropriate merchandise to satisfy the wants of the Chinese language radiotherapy market – the world’s quickest rising – will allow extra folks in China To get the care needed for his or her long-term well being.” Susan WinterPresident and CEO of Accuray Company.

tomo remedy® The platform is the world’s first able to built-in helical fan beam imaging and radiation supply, offering larger management of radiation dose in order that it completely matches the tumor and offers superior regular tissue preservation, enabling the supply of historically segmented therapies into ultra-fractionated therapies. The system is able to treating all commonplace radiotherapy indications together with breast, prostate, lung, stomach, and head and neck cancers, in addition to advanced remedies corresponding to whole marrow irradiation.

“This introduction and regionally manufactured TomoTherapy platform gadget underscore Accuray’s dedication to the three way partnership. I consider Tomo C will meet the necessities of the vast majority of Chinese language clients who want an environment friendly and quick radiological supply system. That is first ChinaThe manufactured system will allow Chinese language clients to ship high-precision radiotherapy to extra sufferers day-after-day.” Roger CowPresident and Normal Supervisor APAC at Accuray.

About Accuray

Accuray is dedicated to increasing the highly effective potential of radiotherapy to enhance the lives of as many individuals as doable. We create distinctive market-changing options designed to ship radiotherapy to even essentially the most advanced circumstances – whereas facilitating generally treatable circumstances – to satisfy the total vary of affected person wants. We’re dedicated to steady innovation in radio-oncology, neuroradiology and extra, partnering with physicians and directors, enabling them to assist sufferers return to their lives sooner. Accuray is headquartered in Sunnyvale, California, with amenities everywhere in the world. To seek out out extra, go to or observe us FacebookAnd the LinkedInAnd the TwitterAnd the Youtube.

Secure Harbor Assertion

Statements on this press launch that aren’t statements of historic information are forward-looking statements and are topic to the “protected harbor” provisions of the Non-public Securities Litigation Reform Act of 1995. Ahead-looking statements on this press launch relate to, however will not be restricted to, anticipated progress drivers. For the corporate, strengthening the three way partnership’s product portfolio, the three way partnership’s capability to compete within the rising sort B section, the power of the Tomo C system to satisfy the wants of Chinese language clients, medical purposes, medical outcomes and affected person outcomes and Accuray’s management place in radiation oncology improvements and applied sciences. These forward-looking statements contain dangers and uncertainties. If any of those dangers or uncertainties materialize, or if any of the Firm’s assumptions show incorrect, precise outcomes may differ materially from the outcomes expressed or implied by these forward-looking statements. These dangers and uncertainties embody, however will not be restricted to, dangers associated to the worldwide macroeconomic setting; The affect of COVID-19; The corporate’s capability to realize widespread market acceptance of its merchandise, together with new product choices and enhancements; The corporate’s capability to develop new merchandise or enhance present merchandise to satisfy buyer wants; and different dangers recognized below “Danger Elements” within the firm’s annual report on Type 10-Ok, filed with the Securities and Alternate Fee (“SEC”) at August 17 2022It’s also up to date periodically with the corporate’s different filings with the Securities and Alternate Fee.

Ahead-looking statements communicate solely as of the date the statements are made and are primarily based on info obtainable to the Firm on the time these statements are made and/or administration’s good religion perception as of that point concerning future occasions. The Firm assumes no obligation to replace forward-looking statements to replicate precise efficiency, outcomes, adjustments in assumptions, or adjustments in different components affecting forward-looking info, besides to the extent required by relevant securities legal guidelines. Accordingly, buyers shouldn’t place undue reliance on any forward-looking statements.

Media connection:
Beth Kaplan
Public Relations Supervisor, Accuray
+1 (408) 789-4426
[email protected]

2 Xia C, Dong X, Li H, Cao M, Solar D, ​​He S, Yang F, Yan X, Zhang S, Li N, Chen W Most cancers Statistics in China And the United State2022: Options, developments and determinants. Chen Med Jie (Engel). 2022 February 9; 135 (5): 584–590. doi: 10.1097/CM9.0000000000002108. PMID: 35143424; PMCID: PMC8920425

Cision View unique content material for multimedia obtain:

SOURCE Accuray Integrated

#Accuray #broadcasts #submission #Tomo #registration #Nationwide #Medical #Merchandise #Administration #China

Leave a Comment

Your email address will not be published.